Rapamycin Ameliorates the CTLA4-Ig-mediated Defect in CD8(+) T Cell Immunity During Gammaherpesvirus Infection

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2015 May 21

PMID 25989700

Citations 8

Authors

D F Pinelli

B S Wakeman

M E Wagener

S H Speck

M L Ford

Affiliations

Soon will be listed here.

Abstract

Latent viral infections are a major concern among immunosuppressed transplant patients. During clinical trials with belatacept, a CTLA4-Ig fusion protein, patients showed an increased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder, thought to be due to a deficient primary CD8(+) T cell response to the virus. Using a murine model of latent viral infection, we observed that rapamycin treatment alone led to a significant increase in virus-specific CD8(+) T cells, as well as increased functionality of these cells, including the ability to make multiple cytokines, while CTLA4-Ig treatment alone significantly dampened the response and inhibited the generation of polyfunctional antigen-specific CD8(+) T cells. However, the addition of rapamycin to the CTLA4-Ig regimen was able to quantitatively and qualitatively restore the antigen-specific CD8(+) T cell response to the virus. This improvement was physiologically relevant, in that CTLA4-Ig treated animals exhibited a greater viral burden following infection that was reduced to levels observed in untreated immunocompetent animals by the addition of rapamycin. These results reveal that modulation of T cell differentiation though inhibition of mTOR signaling can restore virus-specific immune competence even in the absence of CD28 costimulation, and have implications for improving protective immunity in transplant recipients.

Citing Articles

mTOR Deletion Alleviates CD4+ T-Cell Dysfunction in Sepsis through Reducing CTLA4 Accumulation Mediated by Rescuing Autophagy.

Lei X, Zhao G, Xie Y, Cui N Mediators Inflamm. 2024; 2024:4233439.

PMID: 39104632 PMC: 11300103. DOI: 10.1155/2024/4233439.

Evaluation and mechanism study of Pien Tze Huang against EV-A71 infection.

Wang H, Chen F, Wang S, Li Y, Liu T, Li Y Front Pharmacol. 2023; 14:1251731.

PMID: 37954857 PMC: 10637388. DOI: 10.3389/fphar.2023.1251731.

Monoclonal Antibody-Based Therapies for Myasthenia Gravis.

Alabbad S, AlGaeed M, Sikorski P, Kaminski H BioDrugs. 2020; 34(5):557-566.

PMID: 32915379 PMC: 7484611. DOI: 10.1007/s40259-020-00443-w.

Insights into CD8 T Cell Activation and Exhaustion from a Mouse Gammaherpesvirus Model.

Sarawar S, Shen J, Dias P Viral Immunol. 2020; 33(3):215-224.

PMID: 32286179 PMC: 7185348. DOI: 10.1089/vim.2019.0183.

Advances in autoimmune myasthenia gravis management.

Wang S, Breskovska I, Gandhy S, Punga A, Guptill J, Kaminski H Expert Rev Neurother. 2018; 18(7):573-588.

PMID: 29932785 PMC: 6289049. DOI: 10.1080/14737175.2018.1491310.

References

Medina Pestana J, Grinyo J, Vanrenterghem Y, Becker T, Campistol J, Florman S . Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012; 12(3):630-9. DOI: 10.1111/j.1600-6143.2011.03914.x. View

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P . A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10(3):535-46. DOI: 10.1111/j.1600-6143.2009.03005.x. View

Newell E, Sigal N, Bendall S, Nolan G, Davis M . Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity. 2012; 36(1):142-52. PMC: 3752833. DOI: 10.1016/j.immuni.2012.01.002. View

Benavides C, Pollard V, Mauiyyedi S, Podder H, Knight R, Kahan B . BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007; 84(1):83-8. DOI: 10.1097/01.tp.0000268524.27506.39. View

Darrah P, Patel D, De Luca P, Lindsay R, Davey D, Flynn B . Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007; 13(7):843-50. DOI: 10.1038/nm1592. View

Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

Lucas P, Negishi I, Nakayama K, Fields L, Loh D . Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol. 1995; 154(11):5757-68. View

Barton E, Mandal P, Speck S . Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol. 2011; 29:351-97. DOI: 10.1146/annurev-immunol-072710-081639. View

Matas A, Smith J, Skeans M, Lamb K, Gustafson S, Samana C . OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant. 2012; 13 Suppl 1:11-46. DOI: 10.1111/ajt.12019. View

10.

Seder R, Darrah P, Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008; 8(4):247-58. DOI: 10.1038/nri2274. View

11.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

12.

Kaplan B, Qazi Y, Wellen J . Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014; 28(3):126-33. DOI: 10.1016/j.trre.2014.03.002. View

13.

Haririan A, Morawski K, West M, El-Amm J, Doshi M, Cincotta E . Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant. 2007; 21(4):466-71. DOI: 10.1111/j.1399-0012.2007.00669.x. View

14.

Lanzavecchia A, Sallusto F . Understanding the generation and function of memory T cell subsets. Curr Opin Immunol. 2005; 17(3):326-32. DOI: 10.1016/j.coi.2005.04.010. View

15.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View

16.

Huster K, Busch V, Schiemann M, Linkemann K, Kerksiek K, Wagner H . Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A. 2004; 101(15):5610-5. PMC: 397444. DOI: 10.1073/pnas.0308054101. View

17.

Gredmark-Russ S, Cheung E, Isaacson M, Ploegh H, Grotenbreg G . The CD8 T-cell response against murine gammaherpesvirus 68 is directed toward a broad repertoire of epitopes from both early and late antigens. J Virol. 2008; 82(24):12205-12. PMC: 2593319. DOI: 10.1128/JVI.01463-08. View

18.

Saunders R, Metcalfe M, Nicholson M . Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001; 59(1):3-16. DOI: 10.1046/j.1523-1755.2001.00460.x. View

19.

Noel P, Boise L, Green J, Thompson C . CD28 costimulation prevents cell death during primary T cell activation. J Immunol. 1996; 157(2):636-42. View

20.

Ozaki K, Camara N, Galante N, Camargo L, Pacheco-Silva A . Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol. 2004; 5(1):103-6. DOI: 10.1016/j.intimp.2004.09.008. View